BridgeBio Pharma Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Okay. We will continue with the next session, which is BridgeBio Pharma. Good morning, everyone. I'm Paul Choi, the SMid cap biotechnology analyst here at Goldman Sachs. And it's my great pleasure to introduce the founder and CEO of BridgeBio, Neil Kumar, who will walk us through some opening comments on the BridgeBio story. After that, we'll go into Q&A. And as in previous sessions, if investors or clients have comments or questions for the management, in this case Neil, please feel free to submit them through the Goldman Sachs research portal. And time permitting at the end, we'll try and squeeze in a question or 2. Alternatively, you can submit questions to me directly, and I'll read them at the end, as I mentioned.
And with that, I'll turn it over to Neil for some opening comments and then we'll go into Q&A.
Great. Thanks, Paul. Really appreciate the opportunity to present and field
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |